PharmaEssentia Submits Supplemental BLA for BESREMi Label Expansion to FDA
I'm PortAI, I can summarize articles.
PharmaEssentia Corporation has submitted a supplemental Biologics License Application to the U.S. FDA for BESREMi® label expansion to treat essential thrombocythemia, based on positive Phase 3 results. The submission includes the BESREMi® injection pen presentation. These submissions are under FDA review.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments